149 related articles for article (PubMed ID: 38760964)
1. Common immunological and prognostic features of lung and bladder cancer via smoking-related genes: PRR11 gene as potential immunotherapeutic target.
Wang Y; Zhu H; Zhang L; He J; Bo J; Wang J; Ding B; Ren M
J Cell Mol Med; 2024 May; 28(10):e18384. PubMed ID: 38760964
[TBL] [Abstract][Full Text] [Related]
2. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
[TBL] [Abstract][Full Text] [Related]
3. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
5. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
6. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
8. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
9. Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
Zhang W; Zhang Q; Che L; Xie Z; Cai X; Gong L; Li Z; Liu D; Liu S
BMC Cancer; 2022 Mar; 22(1):299. PubMed ID: 35313857
[TBL] [Abstract][Full Text] [Related]
10. HEDGEHOG/GLI Modulates the PRR11-SKA2 Bidirectional Transcription Unit in Lung Squamous Cell Carcinomas.
Sun Y; Xu D; Zhang C; Wang Y; Zhang L; Qiao D; Bu Y; Zhang Y
Genes (Basel); 2021 Jan; 12(1):. PubMed ID: 33477943
[TBL] [Abstract][Full Text] [Related]
11. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
12. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
Wang K; Chen M; Wu W
World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
[TBL] [Abstract][Full Text] [Related]
13. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
14. Identification of key microRNAs and hub genes in non-small-cell lung cancer using integrative bioinformatics and functional analyses.
Song F; Xuan Z; Yang X; Ye X; Pan Z; Fang Q
J Cell Biochem; 2020 Mar; 121(3):2690-2703. PubMed ID: 31692035
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer.
Wang L; Tong X; Zhou Z; Wang S; Lei Z; Zhang T; Liu Z; Zeng Y; Li C; Zhao J; Su Z; Zhang C; Liu X; Xu G; Zhang HT
Mol Cancer; 2018 Sep; 17(1):140. PubMed ID: 30261900
[TBL] [Abstract][Full Text] [Related]
16. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
17. miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Gao P; Wang H; Yu J; Zhang J; Yang Z; Liu M; Niu Y; Wei X; Wang W; Li H; Wang Y; Sun G
PLoS Genet; 2018 Dec; 14(12):e1007790. PubMed ID: 30557355
[TBL] [Abstract][Full Text] [Related]
18. LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p.
Zhang L; Chi B; Chai J; Qin L; Zhang G; Hua P; Jin C
Mol Biotechnol; 2021 Oct; 63(10):933-940. PubMed ID: 34115289
[TBL] [Abstract][Full Text] [Related]
19. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
[TBL] [Abstract][Full Text] [Related]
20. Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer.
Luo WJ; Tian X; Xu WH; Qu YY; Zhu WK; Wu J; Ma CG; Zhang HL; Ye DW; Zhu YP
J Cell Mol Med; 2021 May; 25(9):4326-4339. PubMed ID: 33797188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
